WCLC: AstraZeneca builds case for growing ADC pipeline with double wins in advanced lung cancer

As part of its hard pivot to oncology in recent years, AstraZeneca made a big bet on next-gen cancer fighters with a multibillion-dollar deal in early 2019 with Daiichi Sankyo for its antibody-drug conjugates. The originally targeted therapy has already made good on its market promise, and now AstraZeneca has high hopes for another.